Biohaven Pharma (NYSE: BHVN) reported Q3 EPS of ($1.91), $0.49 better than the analyst estimate of ($2.40). Revenue for the quarter came in at $135.7 million versus the consensus estimate of $128.4 million.

For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.